- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06059534
Evaluation of the Effects of DracoBelle Nu in Skin Health After Oral Intake
Clinical Evaluation of the Improvement of Skin Health Parameters After Oral Intake of DracoBelle Nu in Human Volunteers
Study Overview
Status
Conditions
Detailed Description
Skin aging refers to the natural process of changes that occur in the skin as individuals get older. It is a complex biological process influenced by both intrinsic (internal) and extrinsic (external) factors. The signs of skin aging include wrinkles, loss of elasticity and firmness, loss of skin density, reduced skin hydration, altered skin barrier effect and alterations in skin pigmentation. Recent studies show that the consumption of nutraceuticals may improve different parameters associated with skin aging. Recently, it has been shown that daily food supplementation with 200 mg of Moldavian dragonhead dry extract (DracoBelleTM Nu) improved the skin hydration, elasticity and increased skin density. In this placebo-controlled study, the investigators aim to investigate the effects of dietary supplementation with DracoBelleTM Nu in different skin parameters associated with age.
The products will be provided in capsules containing placebo or 200 mg of DracoBelleTM Nu. 50 volunteers will ingest the placebo and 50 volunteers will ingest the product DracoBelleTM Nu by oral intake once a day (one capsule a day, preferably in the morning) for 12 weeks. Different parameters will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake. The parameters that will be measured are related to the skin health and skin aging and will be determined as follows:
- The skin elasticity, firmness and fatigue will be measured by the Cutometer in the face skin area.
- Wrinkles (area, length, depth and volume) and roughness of the skin will be measured by the technology Bio3D-MS in the crows-feet and cheek areas.
- The skin density will be measured to determine the thickness of the epidermis and dermis by echography analysis with the UltraScan Echograph in the face skin area.
- Skin hydration will be measured with the Corneometer in the face skin area.
- The skin barrier effect will be measured by quantifying the transepidermal water loss with the Tewameter in the cheek.
- The alterations of the skin pigmentation (area and number of dark spots, and contrast of the dark spots compared to the skin) will be measured with the technology Bio3D-MS.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: David Pajuelo Gamez, PhD
- Phone Number: +34 961 24 32 19
- Email: dpajuelo@bionos.es
Study Contact Backup
- Name: Alfonso Mullor
- Phone Number: +34 961 24 32 19
- Email: administracion@bionos.es
Study Locations
-
-
-
Valencia, Spain, 46026
- Bionos Biotech S.L.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy female volunteers.
- Between 35-60 years old (both included).
- With noticeable wrinkles.
- Subjects with absence of any infectious disease within the 4 weeks previous to the study.
- Informed of the purpose and the protocol of the study and signed a written informed-consent form.
Exclusion Criteria:
- Diagnosis of any diseases such as cardiovascular disease, chronic kidney disease (CKD), gastrointestinal disorder, endocrinological disorder, immunological disorder, metabolic disease.
- Consume more than the recommended alcohol guidelines i.e. >21 alcohol units/week for males and >14 units/week for females (europa.eu).
- Current smoking habit or history of smoking within the past 1 year.
- History of depression, schizophrenia, alcoholism, drug addiction, or mental illness.
- Current or previous intake of contraceptives, female hormones, obesity drugs, absorption inhibitors, antidepressants, or appetite suppressants.
- History of asthma or autoimmune disease Use of oral hormone therapies ie. cortisone or steroids in the 6 months prior to initiation of the study.
- Abnormal liver function or abnormal renal function.
- Blood pressure >140/90 mmHg or hypertension with intake of a diuretic.
- Any condition judged by the investigator to be unsuitable for participation in the study.
- Subjects refrain from the intake of other oral supplements, including antioxidants, dietary supplements, etc.
- Subjects do not alter their mode of contraception 6 weeks prior and during the study.
- Subjects refrain from any intense or invasive cosmetic treatment, alone or by a beautician, such as intense masks, peelings, and other treatments.
- Subjects are free to follow their usual routine of day and night care products.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
This group will be provided with placebo capsules for comparative purposes.
|
Volunteers will be provided with the placebo capsules.
For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
|
Experimental: DracoBelleTM Nu
This group will be provided with DracoBelleTM Nu capsules, which will be compared to the placebo group.
|
Volunteers will be provided with the DracoBelleTM Nu capsules.
For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin density will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake.
Time Frame: Skin density will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
50 volunteers will ingest the placebo and 50 volunteers will ingest the product DracoBelleTM Nu by oral intake once a day (one capsule a day) for 12 weeks.
Skin density will be measured in the face skin area with the UltraScan Echograph, and the unit of measurement will be arbitrary units.
|
Skin density will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
Skin hydration will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake.
Time Frame: Skin hydration will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
50 volunteers will ingest the placebo and 50 volunteers will ingest the product DracoBelleTM Nu by oral intake once a day (one capsule a day) for 12 weeks.
Skin hydration will be measured in the face skin area with the Corneometer, and the unit of measurement will be arbitrary units.
|
Skin hydration will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
Skin barrier effect will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake.
Time Frame: Skin barrier effect will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
50 volunteers will ingest the placebo and 50 volunteers will ingest the product DracoBelleTM Nu by oral intake once a day (one capsule a day) for 12 weeks.
Skin barrier effect will be measured in the face skin area with the Tewameter, and the unit of measurement will be arbitrary units.
|
Skin barrier effect will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
Skin pigmentation will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake.
Time Frame: Skin pigmentation will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
50 volunteers will ingest the placebo and 50 volunteers will ingest the product DracoBelleTM Nu by oral intake once a day (one capsule a day) for 12 weeks.
Skin pigmentation will be measured in the face skin area with the Bio3D-MS, and the unit of measurement will be arbitrary units.
|
Skin pigmentation will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
Skin elasticity will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake.
Time Frame: Skin elasticity will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
50 volunteers will ingest the placebo and 50 volunteers will ingest the product DracoBelleTM Nu by oral intake once a day (one capsule a day) for 12 weeks.
Skin elasticity will be measured in the face skin area with the Cutometer, and the unit of measurement will be arbitrary units.
|
Skin elasticity will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
Skin firmness will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake.
Time Frame: Skin firmness will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
50 volunteers will ingest the placebo and 50 volunteers will ingest the product DracoBelleTM Nu by oral intake once a day (one capsule a day) for 12 weeks.
Skin firmness will be measured in the face skin area with the Cutometer, and the unit of measurement will be arbitrary units.
|
Skin firmness will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
Skin fatigue will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake.
Time Frame: Skin fatigue will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
50 volunteers will ingest the placebo and 50 volunteers will ingest the product DracoBelleTM Nu by oral intake once a day (one capsule a day) for 12 weeks.
Skin fatigue will be measured in the face skin area with the Cutometer, and the unit of measurement will be arbitrary units.
|
Skin fatigue will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
Wrinkles will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake.
Time Frame: Wrinkles will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
50 volunteers will ingest the placebo and 50 volunteers will ingest the product DracoBelleTM Nu by oral intake once a day (one capsule a day) for 12 weeks.
Wrinkles will be measured in the crows feet area with the Bio3D-MS, and the unit of measurement will be arbitrary units.
|
Wrinkles will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
Roughness will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake.
Time Frame: Roughness will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
50 volunteers will ingest the placebo and 50 volunteers will ingest the product DracoBelleTM Nu by oral intake once a day (one capsule a day) for 12 weeks.
Roughness will be measured in the crows feet area with the Bio3D-MS, and the unit of measurement will be arbitrary units.
|
Roughness will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake of the product.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Pajuelo Gamez, PhD, Hospital La Fe
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- DracoBelle_2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Dietary supplementation with placebo.
-
Bionos Biotech S.L.Completed
-
University Hospital, ToursInstitut Cancerologie de l'OuestTerminatedMetastatic Breast Cancer | Estrogen Receptor Positive Tumor | Progesterone Receptor Positive Tumor | HER-2 Negative TumorFrance
-
Bionos Biotech S.L.Active, not recruiting
-
Slovak Academy of SciencesNational Cheng Kung University; Comenius University; University Hospital BratislavaUnknownParkinson Disease | Healthy Volunteers | Mild Cognitive Impairment | Subjective Cognitive ImpairmentSlovakia, Taiwan
-
Wageningen Centre for Food SciencesSEAFOODplusCompletedArrhythmiaUnited Kingdom, Netherlands, Germany, Poland, Belgium, Austria, Czech Republic, Switzerland
-
IMDEA FoodCompletedImmune System and Related DisordersSpain
-
University of NottinghamUniversity Hospitals of Derby and Burton NHS Foundation TrustUnknownColorectal CancerUnited Kingdom
-
Maastricht University Medical CenterCompleted
-
Purdue UniversityCompleted
-
Hospital de SaguntoBiopolis S.L.; Laboratorios Heel EspañaUnknown